Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients

José A. Mata-Marín, René Méndez-Cruz, Carla I. Arroyo-Anduiza, Luis A. Mata-Marín, Jesús Gaytán-Martínez, Juan Asbún-Bojalil

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

8 Citas (Scopus)

Resumen

The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment.

Idioma originalInglés
Páginas (desde-hasta)1321-1326
Número de páginas6
PublicaciónJournal of Medical Virology
Volumen85
N.º8
DOI
EstadoPublicada - ago. 2013

Huella

Profundice en los temas de investigación de 'Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients'. En conjunto forman una huella única.

Citar esto